Description

Rare liver tumors like combined HCC/CCA, fibrolamellar HCC, and haemangioendothelioma pose significant diagnostic and therapeutic challenges. In this episode, we explore the latest insights, controversies, and clinical approaches outlined in the new EASL position paper. Join us to uncover how these advancements can address key hurdles in managing these rare malignancies.

Moderator: Thomas Berg 

Faculty: Ruben de Kleine and Henning Wege

Related episodes

• S6E4: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyond
• S5E13: Basics in decision-making for liver cancer treatment
• S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance

ℹ️ Please click here to access the podcast version of this EASL Studio episode.